BeOne Medicines (ONC) Total Debt (2015 - 2026)

BeOne Medicines (ONC) has reported Total Debt for 12 consecutive years, with $959.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Debt rose 3.84% year-over-year to $959.1 million; the TTM figure through Mar 2026 stood at $959.1 million (up 3.84% YoY), while the FY2025 annual figure was $1.0 billion, changed 0.12% from the prior year.
• Total Debt slipped to $959.1 million in Q1 2026 per ONC's latest filing, from $1.0 billion in the prior quarter.
• Across five years, Total Debt topped out at $1.1 billion in Q3 2024 and bottomed at $191.8 million in Q3 2025.
• Historically, Total Debt has averaged $752.8 million across 5 years, with a median of $886.0 million in 2023.
• Annual changes were most pronounced in 2023 — Total Debt surged 241.88% — and 2025, when it slumped 81.75%.
• BeOne Medicines' Total Debt stood at $259.1 million in 2022, then soared by 241.88% to $886.0 million in 2023, then advanced by 14.9% to $1.0 billion in 2024, then climbed by 0.12% to $1.0 billion in 2025, then decreased by 5.9% to $959.1 million in 2026.
• Business Quant data shows ONC's Total Debt at $959.1 million in Q1 2026, $1.0 billion in Q4 2025, and $191.8 million in Q3 2025.